(Press-News.org) **Embargo: 23.30 [UK time] / 6.30pm [US ET] Monday 28th July 2025**
Peer-reviewed / Modelling study, Review and Opinion / People
Embargoed access to the Commission report and contact details for authors are available in Notes to Editors at the end of the release.
The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest
Over 60% of liver cancers globally are preventable through reduction of risk factors including viral hepatitis, alcohol and metabolic dysfunction-associated steatotic liver disease (MASLD) - a long-term liver condition caused by excess fat in the liver.
The Lancet Commission on liver cancer predicts the share of liver cancer cases caused by a severe form of MASLD called metabolic dysfunction-associated steatohepatitis (MASH) will increase by 35% (8% to 11%) by 2050.
The authors call for increased public, medical and political awareness of the rising risk of MASLD – especially in USA, Europe and Asia - with a focus on high-risk groups, including individuals with diabetes and obesity.
With the number of new liver cancer cases predicted to double over the next 25 years without urgent action, the Commission sets the target of an annual reduction of 2% to 5% in the number of new cases - preventing up to 17 million liver cancer cases and up to 15 million deaths, if achieved.
The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer. The Commission highlights several ways to reduce these risks factors, including increasing the coverage of the hepatitis B vaccine and public health policies targeting obesity and alcohol consumption.
Previous analyses have predicted that the number of new liver cancer cases will nearly double from 870,000 in 2022 to 1.52 million in 2050, primarily due to population growth and ageing populations, with the largest increases expected in Africa. The number of deaths from liver cancer are predicted to grow from 760,000 in 2022 to 1.37 million in 2050. [1]
Liver cancer is already a major cause of death and disability. Globally, it’s the sixth most common cancer and the third leading cause of death from cancer. More than 40% of the global liver cancer cases occur in China, mostly due to relatively high rates of hepatitis B infections in the country.
Chair of the Commission, Prof Jian Zhou, Fudan University (China) says: “Liver cancer is a growing health issue around the world. It is one of the most challenging cancers to treat, with five-year survival rates ranging from approximately 5% to 30%. We risk seeing close to a doubling of cases and deaths from liver cancer over the next quarter of a century without urgent action to reverse this trend.”
First author, Prof Stephen Chan, Chinese University of Hong Kong (Hong Kong, China) adds, “As three in five cases of liver cancer are linked to preventable risk factors, mostly viral hepatitis, alcohol and obesity, there is a huge opportunity for countries to target these risk factors, prevent cases of liver cancer and save lives.”
Changes in the causes of liver cancer
In a novel analysis, the Commission estimates that at least 60% of liver cancers are preventable via control of modifiable risk factors, including hepatitis B virus (HBV), hepatitis C virus HCV, MASLD, and alcohol.
MASH, a severe form of MASLD, is the fastest growing cause of liver cancer globally, followed by alcohol. The Commission projects that the proportion of liver cancer cases associated with MASH are projected to increase from 8% in 2022 to 11% in 2050, and liver cancer cases associated with alcohol are projected to increase from 19% in 2022 to 21% in 2050
In contrast, the proportion of liver cancer cases linked to HBV is expected to decrease from 39% in 2022 to 37% in 2050, while HCV-related cases are projected to drop from 29% to 26% over the same period.
A rising risk factor: MASLD
Approximately a third of the global population are estimated to have MASLD. However, only 20 to 30% of patients with MASLD develop the more severe form of the condition with liver inflammation and damage - called metabolic dysfunction-associated steatohepatitis (MASH).
The rate of MASLD-linked liver cancer is expected to rise over the next decade, particularly in the USA, Europe, and Asia, due to increasing rates of obesity. In the USA, MASLD prevalence continues to climb in parallel with the obesity epidemic; by 2040, over 55% of US adults could have MASLD. [For a case study from the USA: ‘MASLD and ALD as the new face of hepatocellular carcinoma’ – see panel 5, page 17 of the report.]
Commission author, Prof Hashem B El-Serag, Baylor College of Medicine (USA) says, “Liver cancer was once thought to occur mainly in patients with viral hepatitis or alcohol-related liver disease. However, today rising rates of obesity are an increasing risk factor for liver cancer, primarily due to the increase in cases of excess fat around the liver.
“One approach to identify patients at high risk of liver cancer would be to introduce screening for liver damage into routine healthcare practice for patients at high risk of MASLD, such as individuals living with obesity, diabetes, and cardiovascular disease. Healthcare professionals should also integrate lifestyle counselling into routine care to support patients to transition to a healthy diet and regular physical activity. Furthermore, policy makers must promote healthy food environments via policies such as sugar taxes and clear labelling on products with high fat, salt, and/or sugar.”
Global targets and recommendations
The Commission estimates that if countries can reduce the incidence of liver cancer cases by 2 to 5% each year by 2050, it could prevent nine to 17 million new cases of liver cancer and save eight to 15 million lives.
As more patients live with liver cancer than ever before, in addition to prevention efforts, there is an urgent need for increased research and attention for these patients to improve their quality of life.
The Commission suggests several strategies for reducing the global burden of liver cancer, including:
Governments should intensify efforts to increase HBV vaccination—such as vaccine mandates in high-prevalence countries—and implement universal HBV screening for adults 18+, alongside targeted HCV screening in high-risk areas based on cost-effectiveness.
Policy makers should enact minimum alcohol unit pricing, warning labels, and advertisement restrictions for alcoholic beverages.
National health authorities and cancer control programmes should prioritise investments in public awareness campaigns and deployment of early detection resources.
Professional organisations and the pharmaceutical industry should work together to reduce differences between Eastern and Western regions of the world in the clinical management of liver cancer.
Hospitals and professional organisations should provide palliative care training, with the aim of integrating palliative care in the early phases for patients in need.
[For a full list of the Commission’s ten recommendations for action see table 1, page 4]
Commission author, Prof Valérie Paradis, Beaujon Hospital (France) says, “There is an urgent need to raise awareness within society about the severity of the growing health issue of rising liver cancer cases. Compared with other cancers, liver cancer is very hard to treat but has more distinct risk factors, which help define specific prevention strategies. With joint and continuous efforts, we believe many liver cancer cases can be prevented and both the survival and quality of patients with liver cancer will be considerably improved.”
NOTES TO EDITORS
This Commission was supported by grants from the Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, and Shanghai Municipal Science and Technology Major Project. A full list of authors and their institutions is available in the report.
Quotes from authors cannot be found in the text of the Commission but have been supplied for the press release.
References:
[1] Bray F, Laversanne M, Sung HYA, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–63.
END
The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest
2025-07-28
ELSE PRESS RELEASES FROM THIS DATE:
Tiny artificial cells can keep time, study finds
2025-07-28
A team of UC Merced researchers has shown that tiny artificial cells can accurately keep time, mimicking the daily rhythms found in living organisms. Their findings shed light on how biological clocks stay on schedule despite the inherent molecular noise inside cells.
The study, recently published in Nature Communications, was led by bioengineering Professor Anand Bala Subramaniam and chemistry and biochemistry Professor Andy LiWang. The first author, Alexander Zhang Tu Li, earned his Ph.D. in Subramaniam’s lab.
Biological clocks — also known as circadian rhythms — govern 24-hour cycles that regulate sleep, metabolism and other vital processes. ...
How aging quiets lupus and brings relief to some older patients
2025-07-28
UCSF researchers have found that certain antiviral genes become less active over time in lupus, revealing why some patients see their symptoms fade as they age.
Lupus is a “classic” autoimmune disease.
It causes the immune system’s first-line viral defenses — known as interferons — to attack the body. Nearly every organ is at risk, leading to conditions like kidney and heart disease.
But unlike many other autoimmune or chronic illnesses, lupus can improve as patients reach their 60s and 70s.
“I see my younger lupus patients in their 20s, 30s, and 40s every few months, monitoring them closely for signs of severe disease, but ...
Research alert: Synergistic treatment approach supercharges cancer immunotherapy
2025-07-28
Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose. With 890,000 new cases and 450,000 deaths annually, HNSCC accounts for roughly 4.5% of cancer diagnoses and deaths worldwide. Treatment options for HNSCC are very limited, so nearly half of affected patients with HNSCC die from the disease. Current therapies consist of surgery, radiotherapy and chemotherapy, which can be effective but often have limited success and significant side effects.
To meet this ...
White veteran high users of online portal generate and exchange more messages than certain patient minorities in the Veterans Health Administration
2025-07-28
Background and Goal: Use of secure messaging, which lets patients communicate with clinicians or care teams through an online portal, has increased in recent years. While secure messaging can increase access to care, answering a high volume of messages can burden care teams. Researchers examined the percentage of all secure messages that were exchanged between primary care teams and high users and whether high users were also heavy users of other primary care or emergency department services.
Study approach: Researchers analyzed data from the VHA Corporate Data Warehouse, the Patient-Centered Management Module web application ...
Web-based tool helps Michigan physicians navigate diabetes coverage and prior authorization
2025-07-28
Michigan’s Collaborative for Type 2 Diabetes (MCT2D), a statewide population health collaborative quality initiative, analyzed nearly 1,000 physician-submitted patient case summaries and needs assessments, finding that physicians needed help managing the burden of prior authorization. The team first developed a PDF guide that was posted on their website in 2021. In 2024, they created an interactive web tool, Coverage Checker, co-designed with MCT2D clinicians. The tool shows care team members whether a patient’s insurance covers guideline-directed medical therapy or continuous glucose monitors and the prior authorization steps each plan requires. Coverage Checker encompasses ...
Most primary care patients with opioid use disorder who start treatment stay engaged
2025-07-28
Background and Goal: Opioid use disorder (OUD) medication treatment saves lives, yet fewer than one-third of people with OUD receive evidence-based treatment with medication. Researchers examined how often adults who report opioid use and moderate or severe substance-use symptoms begin, and stay on, OUD medication.
Study Approach: Researchers reviewed electronic health record and insurance claims data from 33 primary care clinics in Washington from March 1, 2015, to Jan. 1, 2023. The study included 1,502 adults who, at or just before a primary care visit, completed a substance-use checklist, said they had used opioids in the past year, and had not received ...
U.S.-born Latinos have higher rates of obesity compared to foreign-born Latino and white youth
2025-07-28
Background and Goal: Childhood obesity rates differ by ethnicity, yet data on nativity for Latino youth in primary care are limited. Researchers used community health center electronic health records (EHR) from 2012-2020 to track obesity trends by ethnicity and nativity and to test whether nativity is linked to obesity prevalence among patients aged 9-17 years.
Study Approach: Researchers examined EHR data for 147,376 children who visited 1,311 community-based health centers in 21 states. They divided the 2012-2020 span into four snapshots and, at every visit, noted whether ...
Study finds veterans experiencing homelessness who gain housing are more likely to get colorectal and breast cancer screenings
2025-07-28
Original Research
Background and Goal: This study examines if gaining housing increased rates of colorectal and breast cancer screening in a cohort of veterans who experience homelessness.
Study Approach: Researchers reviewed ten years of Veterans Health Administration (VA) records (2011-2021). They identified all veterans who were homeless and overdue for colorectal or breast cancer screening at their first VA clinic visit in the most recent year (the “index” visit). Housing status was then tracked for 24 ...
Body fat percentage beats BMI in predicting 15-year mortality risk among U.S. adults ages 20 to 49
2025-07-28
Background and Goal: Although body mass index (BMI) is widely used in clinics as the standard measure of body composition, it can potentially misclassify muscular individuals as overweight and miss cases of "normal-weight obesity," masking serious metabolic and heart disease risks. This study examined BMI vs body fat percentage for 15-year mortality risk among adults aged 20-49 years.
Study Approach: Researchers from the University of Florida analyzed data from 4,252 participants in the 1999-2004 National Health and Nutrition ...
Umbrella review summarizes family physicians’ experiences with clinical integration
2025-07-28
Background and Goal: Clinical integration involves coordinating ongoing health care services across health professionals, facilities, and support systems to meet patient care needs. Researchers aimed to map out barriers and facilitators perceived by family physicians in clinical integration to guide future intervention development.
Study Approach: Researchers examined systematic review studies published from 2010 to 2022. Researchers adopted a “best-fit framework approach” to organize findings into themes and subthemes. They then validated the framework with another 21 reviews published between 2022 and 2024.
Main Results: ...